Suppr超能文献

柬埔寨北部与哌喹耐药相关的恶性疟原虫氯喹耐药转运体突变的分布和时间动态。

Distribution and Temporal Dynamics of Plasmodium falciparum Chloroquine Resistance Transporter Mutations Associated With Piperaquine Resistance in Northern Cambodia.

机构信息

Malaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

出版信息

J Infect Dis. 2021 Sep 17;224(6):1077-1085. doi: 10.1093/infdis/jiab055.

Abstract

BACKGROUND

Newly emerged mutations within the Plasmodium falciparum chloroquine resistance transporter (PfCRT) can confer piperaquine resistance in the absence of amplified plasmepsin II (pfpm2). In this study, we estimated the prevalence of co-circulating piperaquine resistance mutations in P. falciparum isolates collected in northern Cambodia from 2009 to 2017.

METHODS

The sequence of pfcrt was determined for 410 P. falciparum isolates using PacBio amplicon sequencing or whole genome sequencing. Quantitative polymerase chain reaction was used to estimate pfpm2 and pfmdr1 copy number.

RESULTS

Newly emerged PfCRT mutations increased in prevalence after the change to dihydroartemisinin-piperaquine in 2010, with >98% of parasites harboring these mutations by 2017. After 2014, the prevalence of PfCRT F145I declined, being outcompeted by parasites with less resistant, but more fit PfCRT alleles. After the change to artesunate-mefloquine, the prevalence of parasites with amplified pfpm2 decreased, with nearly half of piperaquine-resistant PfCRT mutants having single-copy pfpm2.

CONCLUSIONS

The large proportion of PfCRT mutants that lack pfpm2 amplification emphasizes the importance of including PfCRT mutations as part of molecular surveillance for piperaquine resistance in this region. Likewise, it is critical to monitor for amplified pfmdr1 in these PfCRT mutants, as increased mefloquine pressure could lead to mutants resistant to both drugs.

摘要

背景

疟原虫氯喹耐药转运蛋白(PfCRT)中出现的新突变可在没有扩增的质体蛋白酶 II(pfpm2)的情况下赋予哌喹耐药性。在这项研究中,我们估计了 2009 年至 2017 年在柬埔寨北部采集的疟原虫分离株中共同循环的哌喹耐药突变的流行率。

方法

使用 PacBio 扩增子测序或全基因组测序确定了 410 株疟原虫PfCRT 的序列。定量聚合酶链反应用于估计 pfpm2 和 pfmdr1 拷贝数。

结果

2010 年改用二氢青蒿素-哌喹后,新出现的 PfCRT 突变的流行率增加,到 2017 年,超过 98%的寄生虫携带这些突变。2014 年后,PfCRT F145I 的流行率下降,被耐药性较低但更适合 PfCRT 等位基因的寄生虫所取代。改用青蒿琥酯-甲氟喹后,携带扩增 pfpm2 的寄生虫的流行率下降,近一半的哌喹耐药 PfCRT 突变体只有单拷贝 pfpm2。

结论

缺乏 pfpm2 扩增的 PfCRT 突变体的比例很大,这强调了在该地区将 PfCRT 突变作为哌喹耐药性分子监测的一部分的重要性。同样,监测这些 PfCRT 突变体中扩增的 pfmdr1 也至关重要,因为增加的甲氟喹压力可能导致对这两种药物都耐药的突变体。

相似文献

引用本文的文献

1
The plasmepsin-piperaquine paradox persists in Plasmodium falciparum.恶性疟原虫中血浆蛋白酶-哌喹矛盾现象仍然存在。
PLoS Pathog. 2025 Jul 28;21(7):e1012779. doi: 10.1371/journal.ppat.1012779. eCollection 2025 Jul.
2
Malaria: past, present, and future.疟疾:过去、现在与未来。
Signal Transduct Target Ther. 2025 Jun 17;10(1):188. doi: 10.1038/s41392-025-02246-3.
4
Temporal and spatial dynamics of Plasmodium falciparum clonal lineages in Guyana.圭亚那疟原虫无性系谱系的时空动态。
PLoS Pathog. 2024 Jun 13;20(6):e1012013. doi: 10.1371/journal.ppat.1012013. eCollection 2024 Jun.
9
Plasmodium falciparum resistance to artemisinin-based combination therapies.恶性疟原虫对青蒿素类复方疗法的抗药性。
Curr Opin Microbiol. 2022 Oct;69:102193. doi: 10.1016/j.mib.2022.102193. Epub 2022 Aug 22.
10
Plasmodium falciparum resistance to ACTs: Emergence, mechanisms, and outlook.恶性疟原虫对青蒿素类复方药物的抗药性:出现、机制和展望。
Int J Parasitol Drugs Drug Resist. 2021 Aug;16:102-118. doi: 10.1016/j.ijpddr.2021.05.007. Epub 2021 May 26.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验